Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$6.48 -5.0%	$10.18	$3.52 ▼ $23.40	$311.52M	0.82	2.69 million shs	1.28 million shs
CNTX Context Therapeutics	$0.84 +1.3%	$0.67	$0.49 ▼ $2.75	$74.45M	1.88	190,974 shs	199,068 shs
NGNE Neurogene	$22.81 -1.2%	$19.58	$6.88 ▼ $74.49	$329.31M	1.51	213,585 shs	96,399 shs
RNAC Cartesian Therapeutics	$13.46 +0.5%	$10.87	$8.46 ▼ $26.50	$347.53M	0.36	85,184 shs	34,336 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+4.60%	-5.80%	-11.20%	-48.64%	+42.68%
CNTX Context Therapeutics	+0.34%	+0.58%	+47.32%	-17.00%	-62.61%
NGNE Neurogene	+5.24%	+2.44%	+34.09%	+50.23%	-46.34%
RNAC Cartesian Therapeutics	+9.93%	+0.90%	+36.22%	+11.12%	-21.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	2.6504 of 5 stars	4.6	1.0	1.6	0.8	0.6
CNTX Context Therapeutics	3.3459 of 5 stars	3.6	3.0	3.1	1.7	1.3
NGNE Neurogene	3.5826 of 5 stars	4.4	2.0	3.2	2.5	0.6
RNAC Cartesian Therapeutics	1.6943 of 5 stars	3.4	1.0	0.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.11	Buy	$22.56	248.08% Upside
CNTX Context Therapeutics	3.17	Buy	$5.50	554.14% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	102.40% Upside
RNAC Cartesian Therapeutics	2.83	Moderate Buy	$40.00	197.18% Upside

Current Analyst Ratings Breakdown

Latest CNTX, NGNE, CAPR, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $24.00
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/30/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/26/2025	CNTX Context Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$4.50 ➝ $4.00
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
6/24/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$17.36M	17.05	N/A	N/A	$3.20 per share	2.03
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$1.27 per share	N/A
NGNE Neurogene	$930K	349.75	N/A	N/A	$20.89 per share	1.09
RNAC Cartesian Therapeutics	$38.91M	8.98	N/A	N/A	($0.27) per share	-49.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$40.47M	-$1.42	N/A	N/A	N/A	-181.71%	-62.42%	-48.36%	8/6/2025 (Estimated)
CNTX Context Therapeutics	-$26.73M	-$0.31	N/A	N/A	N/A	N/A	-29.78%	-29.08%	8/6/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-7.01%	8/6/2025 (Estimated)

Latest CNTX, NGNE, CAPR, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	RNAC Cartesian Therapeutics	-$0.77	N/A	N/A	N/A	$0.77 million	N/A
8/8/2025	Q2 2025	NGNE Neurogene	-$1.15	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	N/A	N/A	N/A	$2.60 million	N/A
8/6/2025	Q1 2025	CNTX Context Therapeutics	-$0.06	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	6.55	6.55
CNTX Context Therapeutics	N/A	48.81	48.81
NGNE Neurogene	N/A	21.03	21.03
RNAC Cartesian Therapeutics	N/A	12.34	12.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
CNTX Context Therapeutics	14.03%
NGNE Neurogene	52.37%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	10.50%
CNTX Context Therapeutics	2.80%
NGNE Neurogene	11.64%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	101	45.68 million	40.88 million	Optionable
CNTX Context Therapeutics	7	89.70 million	87.19 million	Not Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable

CNTX, NGNE, CAPR, and RNAC Headlines

Recent News About These Companies

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?

July 24 at 8:40 AM | zacks.com

Brokers Set Expectations for RNAC Q2 Earnings

July 11, 2025 | marketbeat.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 9, 2025 | marketbeat.com

Cartesian Therapeutics (NASDAQ:RNAC) Earns Outperform Rating from Analysts at Wedbush

July 9, 2025 | marketbeat.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

Cartesian Therapeutics Announces New Employment Inducement Grants

May 2, 2025 | globenewswire.com

Cartesian Therapeutics management to meet with BTIG

April 26, 2025 | markets.businessinsider.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%

April 22, 2025 | aaii.comA

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%

April 15, 2025 | aaii.comA

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 21.84%

April 15, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, NGNE, CAPR, and RNAC Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$6.48 -0.34 (-4.99%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 -0.02 (-0.31%)

As of 07:53 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Context Therapeutics NASDAQ:CNTX

$0.84 +0.01 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.87 +0.03 (+3.95%)

As of 07:56 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Neurogene NASDAQ:NGNE

$22.81 -0.28 (-1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$22.72 -0.09 (-0.39%)

As of 04:10 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Cartesian Therapeutics NASDAQ:RNAC

$13.46 +0.07 (+0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$13.46 +0.00 (+0.04%)

As of 04:10 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time